Belimumab (LymphoSTAT B) [356547-88-1]

BPS Bioscience

Belimumab (LymphoSTAT B) [356547-88-1]

23

Functional Assay, Flow Cytometry

356547-88-1

Research Use Only

Monoclonal

≥95% by SEC-HPLC.

TNFSF13B

TNF superfamily member 13b

BAFF, BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4, tumor necrosis factor ligand superfamily member 13B, ApoL related ligand TALL-1, B-cell-activating factor, B-lymphocyte stimulator, Delta4 BAFF, TNF and ApoL-related leukocyte expressed ligand 1, TNF homolog that activates apoptosis, delta BAFF, dendritic cell-derived TNF-like molecule, epididymis secretory sperm binding protein, tumor necrosis factor (ligand) superfamily, member 13b, tumor necrosis factor (ligand) superfamily, member 20, tumor necrosis factor ligand 7A, tumor necrosis factor superfamily member 13b, tumor necrosis factor-like protein ZTNF4

IgG1

Tumor necrosis factor ligand superfamily member 13B

Belimumab, also known as LymphoStat B, is a humanized IgG1 lambda monoclonal antibody that targets BAFF (TNF family ligand B-cell Activating Factor). Belimumab antagonizes BAFF activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab is been tested in the context of systemic lupus erythematosus (SLE).

2°C to 8°C

41116161

Human